Integra LifeSciences Reports 2Q16 Revenue
ORTHOWORLD estimates Integra LifeSciences' (IART) 2Q16 orthopaedic revenue at US $27.8MM, +39.1% from 2Q15 as-reported.
ORTHOWORLD estimates 2Q16 segment sales and growth on an as-reported basis, as follows.
- Joint Reconstruction Extremities $5.7MM, +43.3%
- Trauma $22.1MM, +38.0%
Joint Reconstruction Extremities growth was led by the Titan Shoulder. Also, within the quarter, IART launched the Fin-Lock™ Glenoid component for the Titan Modular Shoulder system.
Additionally, leadership mentioned strong sales of the Salto Talaris® ankle (acquired from Tornier in 4Q15). Launch of the Cadence™ total ankle is on track, with the first U.S. clinical use and the first ex-U.S. surgery taking place.
Legacy IART lower extremity foot reconstruction product sales were noted to have increased slightly, as well.
Sources: Integra LifeSciences Holdings Corporation; ORTHOWORLD Inc.